Characterize Idiopathic Pulmonary Fibrosis using Respiratory Oscillometry

J. Wu (Toronto, Canada), A. Vasileva (Toronto, Canada), E. Chang (Toronto, Canada), J. Ma (Toronto, Canada), Q. Huang (Toronto, Canada), A. Cassano (Toronto, Canada), M. Binnie (Toronto, Canada), S. Shapera (Toronto, Canada), J. Fisher (Toronto, Canada), C. Ryan (Toronto, Canada), C. Chow (Toronto, Canada)

Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries
Session: Real life in the field of idiopathic pulmonary fibrosis: treatments and registries
Session type: E-poster session
Number: 1858

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
J. Wu (Toronto, Canada), A. Vasileva (Toronto, Canada), E. Chang (Toronto, Canada), J. Ma (Toronto, Canada), Q. Huang (Toronto, Canada), A. Cassano (Toronto, Canada), M. Binnie (Toronto, Canada), S. Shapera (Toronto, Canada), J. Fisher (Toronto, Canada), C. Ryan (Toronto, Canada), C. Chow (Toronto, Canada). Characterize Idiopathic Pulmonary Fibrosis using Respiratory Oscillometry. 1858

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Is Pulmonary Rehabilitation A Savior In Idiopathic Pulmonary Fibrosis?
Source: Virtual Congress 2020 – News on diagnosis and therapy of idiopathic pulmonary fibrosis
Year: 2020


Treatment of Idiopathic Pulmonary Fibrosis
Source: Guideline 2015
Year: 2015

Association between Pulmonary Infections and the Prognosis in Patients with Idiopathic Pulmonary Fibrosis
Source: Virtual Congress 2021 – Interstitial lung disease around the world
Year: 2021


Clinical Features and Prognosis of Acute exacerbation of Connective Tissue Diseases Associated Pulmonary Fibrosis------ Comparision with Idiopathic Pulmonary Fibrosis
Source: International Congress 2017 – The spectrum of CTDs: from pathogenesis to treatment
Year: 2017


Comparison of Impulse Oscillometry With Spirometry in Patients With Non Cystic Fibrosis Bronchiectasis
Source: Virtual Congress 2020 – Respiratory physiology and sleep: new approaches to diagnosis and treatment
Year: 2020


Tele-rehabilitation program in Idiopathic Pulmonary Fibrosis
Source: International Congress 2019 – M-health/e-health I
Year: 2019


The Effects Of Respiratory Viruses on The Acute Pulmonary Exacerbations In Cystic Fibrosis Patients
Source: International Congress 2019 – Insights into paediatric bronchology
Year: 2019


Clinical Correlates of Physical Activity in Idiopathic Pulmonary Fibrosis (IPF)
Source: International Congress 2019 – Pulmonary rehabilitation for non-obstructive lung diseases
Year: 2019

Development Of A Machine Learning Combination With Deep Learning For Diagnosing Idiopathic Pulmonary Fibrosis In Chronic Interstitial Lung Disease
Source: Virtual Congress 2020 – Predictive markers of progression in connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis
Year: 2020


The Value of Voluntary Cough Sounds for Diagnosis of Pulmonary Disease
Source: International Congress 2018 – Clinical determinants of asthma and biomarkers
Year: 2018



Potential benefits of Nordic Walking for Idiopathic Pulmonary Fibrosis
Source: International Congress 2019 – Treatment and prognosis of idiopathic interstitial pneumonia
Year: 2019

Treatment of Idiopathic Pulmonary Fibrosis - Executive Summary
Source: Guideline 2015
Year: 2015

Bacterial Contamination of Home Nebulizers in Children with Cystic Fibrosis and Clinical Implication on the Number of Pulmonary Exacerbations
Source: International Congress 2019 – Infection and inflammation in cystic fibrosis
Year: 2019


Prognostic Factors in Patients with Idiopathic Pulmonary Fibrosis; Evaluation using Quantitative CT Analysis of Fibrosis and Emphysema
Source: International Congress 2019 – Innovations in idiopathic pulmonary fibrosis
Year: 2019


A Minimal Clinically Important Difference for CAMPHOR in Idiopathic Pulmonary Arterial Hypertension
Source: Virtual Congress 2020 – Clinical evaluation, biomarkers and risk assessment of pulmonary hypertension
Year: 2020


Methylprednisolone pulse therapy in Acute Exacerbations of Idiopathic Pulmonary Fibrosis
Source: Virtual Congress 2020 – Prognosis and biomarkers of idiopathic pulmonary fibrosis
Year: 2020


Prevalence and Characteristics of Patients Receiving Antifibrotic Therapy for Idiopathic Pulmonary Fibrosis
Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries
Year: 2020


Platelet activation indices in patients with Idiopathic Pulmonary Fibrosis
Source: International Congress 2014 – ILDs 5
Year: 2014


Epidemiology of Idiopathic Pulmonary Fibrosis in Australia
Source: Virtual Congress 2021 – Interstitial lung disease around the world
Year: 2021


Impulse Oscillometry in Chronic Obstructive Pulmonary Disease
Source: International Congress 2019 – Respiratory function assessment in disease
Year: 2019